Ergosterol biosynthesis and drug development for Chagas disease (Q43276756)

18 November 2017

Ergosterol biosynthesis and drug development for Chagas disease (English)

1 reference

18 November 2017

0 references

Julio A Urbina

1

1 reference

PubMed ID

19753490

18 November 2017

language of work or name

1 reference

1 July 2009

1 reference

Memórias do Instituto Oswaldo Cruz

18 November 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

18 November 2017

104 Suppl 1

1 reference

18 November 2017

311-318

1 reference

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model

18 November 2017

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Cloning and heterologous expression of the Trypanosoma brucei lanosterol synthase gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Nova entidade morbida do homem: rezumo geral de estudos etiolojicos e clinicos

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

A critical review on Chagas disease chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Sensitivity of parasites to free radical damage by antiparasitic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against Trypanosoma cruzi

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Ethiologic treatment of acute and chronic Chagas' Disease [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Molecular medicine. The cholesterol quartet

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Oxidosqualene cyclase inhibitors as antimicrobial agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Prevention, control, and elimination of neglected diseases in the Americas: pathways to integrated, inter-programmatic, inter-sectoral action for health and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Synthesis and biological evaluation of quinuclidine derivatives incorporating phenothiazine moieties as squalene synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Autoimmunity in chagas disease cardiomyopathy: Fulfilling the criteria at last?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Parasitic diseases of the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Rational modification of a candidate cancer drug for use against Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Pathogenesis of chronic Chagas heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Squalene synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Penetration of ravuconazole, a new triazole antifungal, into rat tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Health Innovation Networks to Help Developing Countries Address Neglected Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Ten years of experience with amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

The future of Chagas disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Parasite persistence in the aetiology of Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Chagas disease: a role for autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

The challenges of Chagas Disease-- grim outlook or glimmer of hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Chagas disease etiology: autoimmunity or parasite persistence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

"Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Chemotherapy of Chagas' disease: the how and the why.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Chemotherapy of Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Specific chemotherapy of Chagas disease: controversies and advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Preclinical pharmacokinetics of benznidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762009000900041

10.1590/S0074-02762009000900041

21 January 2018

Identifiers

DOI

1 reference

release_huil4ywy2jhydpd3jzqylzh5x4

18 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/huil4ywy2jhydpd3jzqylzh5x4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

19753490

1 reference

PubMed ID

19753490